KLRSHealthcare · BiotechnologyKLRS Stock Forecast: Kalaris Therapeutics, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Kalaris Therapeutics, Inc. hold a median 12-month price target of $20 — +393.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
KLRS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Kalaris Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (78): Smaller than most of the companies we track.
Value (8): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Kalaris Therapeutics, Inc. — and when they’d sell — is the membership.
KLRS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KLRS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +393.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 June 2026 | TD Cowen | Initiates | Buy | — |
| 14 May 2026 | Wedbush | Initiates | Outperform | — |
| 13 May 2026 | Citizens | Maintains | Market Outperform | — |
| 16 Apr 2026 | Morgan Stanley | Initiates | Overweight | — |
| 23 Dec 2025 | Chardan Capital | Initiates | Buy | — |
| 3 Nov 2025 | Citizens | Initiates | Market Outperform | — |
| 3 Sept 2025 | Raymond James | Initiates | Strong Buy | — |
| 8 Apr 2025 | William Blair | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KLRS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Kalaris Therapeutics, Inc. (KLRS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.2×
- Price / sales
- —
- Price / book
- 1.2×
- EV / EBITDA
- 0.3×
Cheaper than 83% of US stocks
Cheaper than 67% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −66.6%
- Return on assets
- −28.0%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
KLRS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KLRS appears on the weeks it earns a place.
Frequently asked questions about KLRS stock
What is the KLRS stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Kalaris Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $7 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KLRS stock a buy right now?
Of the 8 analysts covering Kalaris Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kalaris Therapeutics, Inc. 21 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KLRS?
As at 1 Aug 2026, Kalaris Therapeutics, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (78 of 100).
Will KLRS stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +393.8% from the last close, and Ticker Nerd's factor model ranks Kalaris Therapeutics, Inc. 21 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KLRS stock forecast for 2030?
No analyst covering Kalaris Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KLRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $25 over the next 12 months.
How has KLRS stock performed over the past year?
Kalaris Therapeutics, Inc. returned +50.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Kalaris Therapeutics, Inc. do?
Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for prevalent retinal diseases with major unmet medical needs.
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for prevalent retinal diseases with major unmet medical needs. Its lead asset, TH103, is an investigational dual-targeting biologic designed for intravitreal delivery to treat exudative and neovascular retinal conditions, including wet age-related macular degeneration, diabetic eye disease, and retinal vein occlusion. TH103 features extended intraocular retention and enhanced VEGF inhibition through optimized binding to VEGF receptor ligands and heparan sulfate proteoglycan anchoring, aiming to reduce the frequency of clinic visits required by existing therapies. The company is advancing TH103 in clinical trials, such as a Phase 1b/2 multi-dose study in neovascular AMD. Kalaris Therapeutics, Inc. addresses significant burdens on patients and caregivers by pursuing treatments that could improve vision preservation with potentially longer-lasting effects. Headquartered in Palo Alto, California, it operates in the ophthalmology sector, targeting transformative solutions for retinal health.
CEO Mr. Andrew Oxtoby · 20 employees · United States · https://kalaristx.com